CTLA4 and non-small cell lung carcinoma: For example, combination therapy with anti-CTLA-4 plus anti-PD-1/PD-L1 has shown an outperformed therapeutic effect over single ICIs treatment in melanoma and non-small cell lung cancer (NSCLC) (Chae et al., 2018).